Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - oxycodone hydrochloride, quantity: 50 mg - injection, solution - excipient ingredients: citric acid monohydrate; hydrochloric acid; sodium citrate dihydrate; water for injections; sodium hydroxide; sodium chloride - oxycodone-hameln solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - oxycodone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: sodium citrate dihydrate; sodium hydroxide; sodium chloride; hydrochloric acid; water for injections; citric acid monohydrate - oxycodone-hameln solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - oxycodone hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium chloride; hydrochloric acid; sodium citrate dihydrate; water for injections; sodium hydroxide - oxycodone-hameln solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

samsung bioepis au pty ltd - infliximab, quantity: 100 mg - injection, powder for - excipient ingredients: water for injections; sucrose; monobasic sodium phosphate monohydrate; polysorbate 80; dibasic sodium phosphate heptahydrate - renflexis is indicated for the treatment of:,rheumatoid arthritis in adults renflexis, in combination with methotrexate, is indicated for the reduction of signs and symptoms and prevention of structural joint damage (erosions and joint space narrowing) in: - patients with active disease despite treatment with methotrexate; - patients with active disease who have not previously received methotrexate.,renflexis should be given in combination with methotrexate. efficacy and safety in rheumatoid arthritis have been demonstrated only in combination with methotrexate,ankylosing spondylitis renflexis is indicated for the reduction of signs and symptoms and improvement in physical function in patients with active disease.,psoriatic arthritis renflexis is indicated for the treatment of the signs and symptoms, as well as for the improvement in physical function in adult patients with active and progressive psoriatic arthritis who have responded inadequately to disease-modifying anti-rheumatic drug (dmard) therapy.,renflexis may be administered in combination with methotrexate.,psoriasis renflexis is indicated for the treatment of adult patients with moderate to severe plaque psoriasis for whom phototherapy or conventional systemic treatments have been inadequate or are inappropriate. safety and efficacy beyond 12 months have not been established.,crohn?s disease in adults and in children and adolescents (6 to 17 years) renflexis is indicated for the treatment of moderate to severe crohn?s disease, to reduce the signs and symptoms and to induce and maintain clinical remission in patients who have an inadequate response to conventional therapies,refractory fistulising crohn?s disease renflexis is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients.,ulcerative colitis in adults and in children and adolescents (6 to 17 years) renflexis is indicated for the treatment of moderately severe to severe active ulcerative colitis in patients who have had an inadequate response to conventional therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: (s)-lactic acid; water for injections; sodium hydroxide; sorbitol - for use as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum and in patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: lactic acid; sorbitol; sodium hydroxide; water for injections - irinotecan injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections; lactic acid; sodium hydroxide; sorbitol - irinotecan injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection, concentrated - excipient ingredients: lactic acid; water for injections; hydrochloric acid; sorbitol; sodium hydroxide - irinotecan injection is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan injection is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection, concentrated - excipient ingredients: sorbitol; sodium hydroxide; hydrochloric acid; lactic acid; water for injections - irinotecan injection is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan injection is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection, concentrated - excipient ingredients: lactic acid; water for injections; sorbitol; hydrochloric acid; sodium hydroxide - irinotecan injection is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan injection is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.